Ceftazidime-Avibactam in Critically Ill Patients: A Multicenter Observational Study

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Pharmacology

Background:

• Ceftazidime-avibactam (CAZ-AVI) is an important intravenous antibiotic for Gram-negative bacterial infections.
• Limited data exist on CAZ-AVI's effectiveness and safety in critically ill patient populations.
• This study addresses the need for more evidence in intensive care unit (ICU) settings.

Purpose of the Study:

• To evaluate 30-day clinical outcomes in critically ill patients treated with CAZ-AVI.
• To identify risk factors associated with 30-day clinical failure, including death and recurrence.
• To assess the efficacy and safety of CAZ-AVI in an ICU cohort.

Main Methods:

• A multicenter, retrospective, observational cohort study was conducted in four ICUs.
• Included were 161 adult critically ill patients receiving CAZ-AVI for at least 72 hours.
• Patients were treated for confirmed or suspected Gram-negative bacterial infections.

Main Results:

• CAZ-AVI achieved positive clinical outcomes in 58% of patients, with a 24% overall mortality rate.
• Relapse or persistent infection occurred in 25% of patients, with 26% developing acquired resistance.
• Treatment failure was higher in immunosuppressed patients, especially liver transplant recipients.

Conclusions:

• CAZ-AVI mortality rates in ICU patients are comparable to other studies.
• Rapid emergence of CAZ-AVI resistance highlights the need for antimicrobial stewardship.
• Optimizing pharmacokinetic/pharmacodynamic (PK/PD) properties is crucial for effective CAZ-AVI use in critically ill patients.